Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

  1. Drake, M.J.
  2. Chapple, C.
  3. Esen, A.A.
  4. Athanasiou, S.
  5. Cambronero, J.
  6. Mitcheson, D.
  7. Herschorn, S.
  8. Saleem, T.
  9. Huang, M.
  10. Siddiqui, E.
  11. Stölzel, M.
  12. Herholdt, C.
  13. MacDiarmid, S.
Revista:
European Urology

ISSN: 1873-7560,  0302-2838

Ano de publicación: 2016

Volume: 70

Número: 1

Páxinas: 136-145

Tipo: Artigo

DOI: 10.1016/J.EURURO.2016.02.030 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus